SecBot SecBot

DERM

Journey Medical Corp
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001867066 Biotech & Drug Discovery
$4.97 −0.05 (−1.00%)
Oct 26 4:00 PM ET · prev $5.02
Market cap
$143.7M
Micro cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
$13.50
+172% · range $13.00–15.00
Next earnings
Nov 11
in 15 days
1 year
−38.0%
from $8.02 · Oct 27
30 days
−22.7%
from $6.43
52-week range
$4.39–9.26
−46% from high · low Mar 30
Avg volume 20D
188.1K
shares / day
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 1 bearish · 1 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/4 ·Next Earnings date, Nov 11, 2026
Strongest NEUTRAL Wasatch Advisors LP filed an amended Schedule 13G disclosing a 11.0% passive stake in Journey Medical Corp…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 10 added (0 new), 12 trimmed or exited.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    25% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
WASATCH ADVISORS LPADD2,858,930$20.2M
VANGUARD CAPITAL MANAGEMENT LLCTRIM675,185$4.8M
GEODE CAPITAL MANAGEMENT, LLCTRIM216,004$1.5M
Trexquant Investment LPDOUBLED171,338$1.2M
MILLENNIUM MANAGEMENT LLCTRIM110,016$778.9K
BlackRock, Inc.NEAR_EXIT100,981$714.9K
VANGUARD FIDUCIARY TRUST COTRIM94,729$670.7K
GOLDMAN SACHS GROUP INCADD90,294$639.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy2Buy7Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +172%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 26, 2026🔒 Fresh data, subscribers only
REITERATE
REITERATE
Aug 13, 2026B. Riley Securities
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jul 1, 2026
Herskowitz Neil
Director
AWARD50,000 sh
Jul 1, 2026
Smith Justin Adam
Director
AWARD50,000 sh
Jul 1, 2026
Toledano Miranda Jayne
Director
AWARD50,000 sh
Jun 25, 2026
Smith Justin Adam
Director
AWARD10,000 sh
Jun 25, 2026
ROSENWALD LINDSAY A MD
Director
AWARD10,000 sh
Jun 25, 2026
Pearce Michael Cooper
Director
AWARD10,000 sh
Jun 25, 2026
Herskowitz Neil
Director
AWARD10,000 sh
Jun 25, 2026
Toledano Miranda Jayne
Director
AWARD10,000 sh

Earnings setup

Estimates
Nov 11
reports in 15 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 9, 2026 SEC
Wasatch Advisors LP filed an amended Schedule 13G disclosing a 11.0% passive stake in Journey Medical Corp as of…
SC 13G/A — Impact 4/10
Sep 8, 2026 Other
Journey Medical Corporation to Participate in September 2026 Investor Conferences
SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”
Aug 15, 2026 SEC
Q2 2026 institutional cluster in DERM shows a mixed picture: Wasatch Advisors added $10.2M (+34%), while BlackRock…
INST-CLUSTER — Impact 4/10
Aug 12, 2026 SEC
Journey Medical reported Q2 2026 revenue of $18.5M (+23% YoY), beating the $18.4M consensus, and a narrower GAAP net…
8-K — Impact 6/10
Jul 1, 2026 Insider
Herskowitz Neil was granted 50,000 shares
Director
Jul 1, 2026 Insider
Smith Justin Adam was granted 50,000 shares
Director
Jul 1, 2026 Insider
Toledano Miranda Jayne was granted 50,000 shares
Director
Jun 30, 2026 Inst.
WASATCH ADVISORS LP — ADD
2,858,930 shares ($20.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
DERM Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Sep 8, 2026
Press release
Journey Medical Corporation to Participate in September 2026 Investor Conferences
SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage…
Aug 12, 2026
Earnings
Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter
Aug 12, 2026
Earnings date
DERM Q2 2026 Earnings Scheduled — 2026-08-12
Aug 11, 2026
Earnings date
DERM Q2 2026 Earnings Scheduled — 2026-08-11
May 19, 2026
Press release
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a…

SecBot reports

6 filings · 3 press releases · 2 bullish · 1 bearish · 1 mixed · 2 neutral
All DERM filing & press-release reports (9)